Home
CYCC
CYCC News

Latest Cyclacel Pharmaceuticals Inc. (CYCC) News on December 19, 2024

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

GlobeNewswire

13 days ago

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations

Simply Wall St.

a month ago

Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

GlobeNewswire

a month ago

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

GlobeNewswire

a month ago

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss

Zacks

a month ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

GlobeNewswire

a month ago

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

GlobeNewswire

2 months ago

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

GlobeNewswire

2 months ago

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

GlobeNewswire

2 months ago

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

MT Newswires

2 months ago

Cyclacel Pharmaceuticals Files for Offering of Shares, Warrants

MT Newswires

3 months ago

Cyclacel Completes Enrollment of Biomarker-Based Patients in Phase 2 Fadraciclib Study

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

GlobeNewswire

3 months ago

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

3 months ago

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

GlobeNewswire

3 months ago

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks

4 months ago

Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

4 months ago

Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates

Zacks

4 months ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

GlobeNewswire

4 months ago

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

GlobeNewswire

4 months ago

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know

Zacks

5 months ago

Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know

MT Newswires

6 months ago

Cyclacel Receives Notice of European Patent Grant for Plogosertib; Shares Rise

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

GlobeNewswire

6 months ago

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy

Zacks

6 months ago

All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy

Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

GlobeNewswire

6 months ago

Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer

GlobeNewswire

7 months ago

Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer

GuruFocus.com

7 months ago

Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

GlobeNewswire

7 months ago

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

GlobeNewswire

7 months ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

GlobeNewswire

8 months ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

MT Newswires

8 months ago

Top Midday Gainers

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

8 months ago

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future

Simply Wall St.

8 months ago

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

GlobeNewswire

9 months ago

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript

Insider Monkey

9 months ago

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

9 months ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

GlobeNewswire

9 months ago

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

GlobeNewswire

9 months ago

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

GlobeNewswire

10 months ago

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

GlobeNewswire

a year ago

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Foresight: Rail Vision's Main Line System Secures EU Railway Standards Approval and Certifications

GlobeNewswire

a year ago

Foresight: Rail Vision's Main Line System Secures EU Railway Standards Approval and Certifications

ClearOne to Showcase Conference and Collaboration Solutions for Every Size of Meeting Space at ISE 2024

Business Wire

a year ago

ClearOne to Showcase Conference and Collaboration Solutions for Every Size of Meeting Space at ISE 2024

Genius Group and FatBrain AI Agree to Merge into Growth Platform to Accelerate the Exponential Economy of Tomorrow

GlobeNewswire

a year ago

Genius Group and FatBrain AI Agree to Merge into Growth Platform to Accelerate the Exponential Economy of Tomorrow

WiSA E Leaves an Impressive Mark on CES Attendees

Business Wire

a year ago

WiSA E Leaves an Impressive Mark on CES Attendees

The Return Trends At B.O.S. Better Online Solutions (NASDAQ:BOSC) Look Promising

Simply Wall St.

a year ago

The Return Trends At B.O.S. Better Online Solutions (NASDAQ:BOSC) Look Promising

Versus Systems Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire

a year ago

Versus Systems Regains Compliance with Nasdaq Minimum Bid Price Requirement

Innovative Eyewear, Inc. 2023 Year-end Review

PR Newswire

a year ago

Innovative Eyewear, Inc. 2023 Year-end Review

Save Foods: Nitrousink Files US Patent Application for Reducing Emissions of Nitrous Oxide in Wheat

GlobeNewswire

a year ago

Save Foods: Nitrousink Files US Patent Application for Reducing Emissions of Nitrous Oxide in Wheat

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

GlobeNewswire

a year ago

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

AmpliTech Group Unveils AGTGSS Flagship Product, A Massive MIMO, 64T64R ORAN, CAT B Radio And Launches New AGTGSS Division Website

GlobeNewswire

a year ago

AmpliTech Group Unveils AGTGSS Flagship Product, A Massive MIMO, 64T64R ORAN, CAT B Radio And Launches New AGTGSS Division Website

E-Home Household Services Holdings Limited Signed Property Cleaning Contracts with Shibang Taihe and Jinhui Property in January 2024 for a Total Amount of Over RMB 40 Million

PR Newswire

a year ago

E-Home Household Services Holdings Limited Signed Property Cleaning Contracts with Shibang Taihe and Jinhui Property in January 2024 for a Total Amount of Over RMB 40 Million

Exela Technologies Recognized as a Disruptor in Avasant Research Report

GlobeNewswire

a year ago

Exela Technologies Recognized as a Disruptor in Avasant Research Report

Mainz Biomed Provides Year-End Corporate Review 2023

GlobeNewswire

a year ago

Mainz Biomed Provides Year-End Corporate Review 2023

Are Consumer Staples Stocks Lagging Coca-Cola HBC (CCHGY) This Year?

Zacks

a year ago

Are Consumer Staples Stocks Lagging Coca-Cola HBC (CCHGY) This Year?

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

GlobeNewswire

a year ago

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

PR Newswire

a year ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide

ACCESSWIRE

a year ago

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

GlobeNewswire

a year ago

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

GlobeNewswire

a year ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

Business Wire

a year ago

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

News Direct

a year ago

Tonix Pharmaceuticals announces key topline data from 2nd Phase 3 Clinical Trial of TNX-102 SL

Oilprice.com

a year ago

2023 Was a Bad Year for Commodities

10 Supplements for Longevity and Antiaging: Expert Recommendations

Insider Monkey

a year ago

10 Supplements for Longevity and Antiaging: Expert Recommendations

The Fed Alone Can’t Make Gold Sparkle in 2024

The Wall Street Journal

a year ago

The Fed Alone Can’t Make Gold Sparkle in 2024

One Cyanotech Insider Raised Stake By 42% In Previous Year

Simply Wall St.

a year ago

One Cyanotech Insider Raised Stake By 42% In Previous Year

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

a year ago

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Save Foods: Nitrousink Commenced Controlled Trial for the Reduction of Greenhouse Gas Emissions

GlobeNewswire

a year ago

Save Foods: Nitrousink Commenced Controlled Trial for the Reduction of Greenhouse Gas Emissions

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Business Wire

a year ago

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

GlobeNewswire

a year ago

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Presidio Property Trust Announces Series D Preferred Stock Cash Dividend

GlobeNewswire

a year ago

Presidio Property Trust Announces Series D Preferred Stock Cash Dividend

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction

GlobeNewswire

a year ago

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction

Cyclacel Pharmaceuticals Announces Reverse Stock Split

GlobeNewswire

a year ago

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Know Labs, Inc. to Host Review of Fiscal Year 2023 Results on December 19, 2023

Business Wire

a year ago

Know Labs, Inc. to Host Review of Fiscal Year 2023 Results on December 19, 2023

POET Technologies Earns High Praise from Industry Expert in New e-Book

GlobeNewswire

a year ago

POET Technologies Earns High Praise from Industry Expert in New e-Book

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

GlobeNewswire

a year ago

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Intuitive Machines Nova-C Lunar Lander Arrives in Cape Canaveral, Florida

GlobeNewswire

a year ago

Intuitive Machines Nova-C Lunar Lander Arrives in Cape Canaveral, Florida

Build Better Journalist Relationships with These Three Tips from ACCESSWIRE

ACCESSWIRE

a year ago

Build Better Journalist Relationships with These Three Tips from ACCESSWIRE

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

GlobeNewswire

a year ago

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation

Simply Wall St.

a year ago

Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation

Vivos receives FDA 510(k) clearance for oral devices to treat severe sleep apnea

MedTech Dive

a year ago

Vivos receives FDA 510(k) clearance for oral devices to treat severe sleep apnea

Health Care Roundup: Market Talk

The Wall Street Journal

a year ago

Health Care Roundup: Market Talk

11 Best Coffee Stocks to Invest In

Insider Monkey

a year ago

11 Best Coffee Stocks to Invest In

AmpliTech Group, Inc. Discusses 2023 Revenue Projections and 2024 Technology Applications with The Stock Day Podcast

ACCESSWIRE

a year ago

AmpliTech Group, Inc. Discusses 2023 Revenue Projections and 2024 Technology Applications with The Stock Day Podcast

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

GlobeNewswire

a year ago

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions

Business Wire

a year ago

Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions

Veritone Joins the Generative AI Center of Excellence for AWS Partners

Business Wire

a year ago

Veritone Joins the Generative AI Center of Excellence for AWS Partners

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire

a year ago

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire

a year ago

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

GlobeNewswire

a year ago

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

GlobeNewswire

a year ago

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2023 Earnings Call Transcript

Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML

GlobeNewswire

a year ago

Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML

Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2024

Business Wire

a year ago

Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2024

Team Inc. Names Michael Caliel as Executive Chairman

Hart Energy

a year ago

Team Inc. Names Michael Caliel as Executive Chairman

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

GlobeNewswire

a year ago

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Sarcos Technology and Robotics Corporation to Report Third Quarter 2023 Financial Results

GlobeNewswire

a year ago

Sarcos Technology and Robotics Corporation to Report Third Quarter 2023 Financial Results

Share on Social Networks: